van den Heerik, Anne Sophie V M http://orcid.org/0000-0001-6403-0143
Horeweg, Nanda http://orcid.org/0000-0002-8581-4753
de Boer, Stephanie M
Bosse, Tjalling
Creutzberg, Carien L
Clinical trials referenced in this document:
Documents that mention this clinical trial
ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up
https://doi.org/10.1016/j.radonc.2015.11.013
Management of nodal recurrences of endometrial cancer with IMRT
https://doi.org/10.1016/j.ygyno.2015.07.096
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Documents that mention this clinical trial
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
https://doi.org/10.1136/ijgc-2020-001929
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Adjuvant chemotherapy and radiation for patients with high-risk stage I endometrial cancer treated with curative intent surgery: impact on recurrence and survival
https://doi.org/10.1136/ijgc-2021-003087
Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy
https://doi.org/10.1136/ijgc-2021-002380
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
The time is now to start molecular subtyping high-intermediate and high-risk endometrial cancers
https://doi.org/10.1136/ijgc-2022-003709
Documents that mention this clinical trial
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775
https://doi.org/10.1200/jco.22.02152
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
https://doi.org/10.1136/ijgc-2021-002881
Documents that mention this clinical trial
323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer
https://doi.org/10.1136/ijgc-2020-igcs.277
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
https://doi.org/10.1136/ijgc-2021-003017
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
#88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study
https://doi.org/10.1136/ijgc-2024-esgo.1115
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: a retrospective single-center experience
https://doi.org/10.1136/ijgc-2022-003997
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study
https://doi.org/10.1136/ijgc-2021-002881
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036
Documents that mention this clinical trial
Biomarker-driven therapy in endometrial cancer
https://doi.org/10.1136/ijgc-2022-003676
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
https://doi.org/10.1200/jco.2023.41.16_suppl.tps5628
Documents that mention this clinical trial
Molecular typing guiding treatment and prognosis of endometrial cancer
https://doi.org/10.1016/j.gocm.2023.01.011
Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
https://doi.org/10.1136/ijgc-2020-001822
Funding for this research was provided by:
KWF Kankerbestrijding (12376, UL2011-5336)